{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["pirtobrutinib"]],"indication":"previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma","name":"BRUIN CLL-322","nct_id":"NCT04965493","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=bruin-cll-322-nct04965493. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"BRUIN CLL-322","arms":[{"description":"Fixed duration pirtobrutinib in combination with venetoclax and rituximab","label":"Arm A (PVR)","type":"EXPERIMENTAL"},{"description":"Venetoclax with rituximab","label":"Arm B (VR)","type":"ACTIVE_COMPARATOR"}],"collaborators":["Eli Lilly and Company"],"completion_date":{"date":"2027-10","type":"ESTIMATED"},"conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"enrollment":{"count":600,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pirtobrutinib","otherNames":["LOXO-305","LY3527727"],"type":"DRUG"},{"name":"Venetoclax","otherNames":["Venclexta","Venclyxto"],"type":"DRUG"},{"name":"Rituximab","otherNames":["Rituxan","MabThera","Truxima","Riabni","Ruxience"],"type":"DRUG"}],"last_update":"2026-01-29","lead_sponsor":"Loxo Oncology, Inc.","official_title":"A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-10","type":"ESTIMATED"},"primary_outcomes":[{"measure":"To evaluate progression-free survival (PFS) of pirtobrutinib plus venetoclax and rituximab (Arm A) compared to venetoclax and rituximab (Arm B)","timeFrame":"Up to approximately 5 years"}],"references":[{"citation":"Davids MS, Eyre TA, Woyach JA, Roeker LE, Ferrajoli A, Wang Y, Tam CS, Jurczak W, Zinzani PL, Simkovic M, Li JY, Bosch F, Roos-Weil D, Cramer P, Osterborg A, Islam P, Jacobs R, Skarbnik A, Bhat SA, Kang S, Chen M, Nguyen B, McNeely SC, Chung KL, Oliveira JM, Ito R, Ghia P, Wierda WG. Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet. 2026 Aug 1;408(10553):453-470. doi: 10.1016/S0140-6736(26)01204-3. Epub 2026 Jul 9.","pmid":"42425121","type":"DERIVED"}],"start_date":{"date":"2021-09-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","url":"https://clinicaltrials.gov/study/NCT04965493"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/bruin-cll-322-nct04965493"}